PARIS, FRANCE, April 27, 2020 – PathoQuest,a leading genomic expert in clinical diagnostics and biologics testing applications with innovative next-generation sequencing (NGS) approach, today announced the appointment of Dr. Laurent Lafferrere as company COO. Dr. Laurent Lafferrère has over 20 years of experience in the pharmaceutical industry, in CMC divisions, including 10 years of experience in executive management.
Prior to joining PathoQuest, Dr. Lafferrère was in charge of the SEQENS Lab R&D Center at SEQENS. He led the restarting from scratch in 2017 of the R&D center delivering services for Pharmaceutical, cosmetic, and chemical advanced specialties markets. He created an Ecosystem with CROs and innovation biotechnologies to deliver integrated services for creating more value to pharma clients.
Prior to the above, Dr. Lafferrère held Managing Director position at COVANCE, a CRO, where he changed a former R&D cost center (Sanofi) to a profit center (Covance) He led the development of business lines such as CMC and Preclinical studies in compliance with regulatory requirements, respectively GMP and GLP.
Dr. Lafferrère held several positions in the pharmaceutical industries such as SANOFI and SERVIER in CMC divisions.
Dr. Lafferrère holds a PhD. in Chemical Engineering and Physico-chemistry from the University of Marseille. He completed his post-doctoral training at RHODIA with LAGEP in Lyon, where a part of his works has been patented. More recently, he obtained an Executive MBA degree at HEC Paris with a major in Differentiation and Innovation through services.
“PathoQuest is very proud to add Laurent Lafferrere to our leadership team” stated Jean-Francois Brepson, PathoQuest’s President and CEO. “We are excited to see our team grow and are looking forward to working with him to streamline and grow further our NGS Quality Control business for biologics.”
PathoQuest offers biopharmaceutical companies a game-changing Genomic approach to secure the biosafety of biological drugs like cell & gene therapy products, vaccines, and recombinant. It allows reducing time to market of innovative treatments.
PathoQuest’s technology combines a next-generation sequencing (NGS) platform with a proprietary sample preparation process completed by a proprietary pathogen genome sequence databases and automated analysis pipeline.
PathoQuest has signed in 2018 a strategic partnership with Charles River Lab (Boston, USA).
Based on its technological platform, PathoQuest has also developed a metagenomic test direct from blood (iDTECT®) to improve the diagnosis of Bloodstream infections and fight against Antimicrobial Resistance (AMR).